Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme
- PMID: 28011470
- DOI: 10.21873/anticanres.11285
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme
Abstract
Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor in adults with generally dismal prognosis, early clinical deterioration and high mortality. GBM is extremely invasive, characterized by intense and aberrant vascularization and high resistance to multimodal treatment. Standard therapy (surgery, radiotherapy and chemotherapy with temozolomide) has very limited effectiveness, with median overall survival of patients no longer than 15 months. Progress in genetics and epigenetics of GBM over the past decade has revealed various aberrations in cellular signaling pathways, the tumor microenvironment, and pathological angiogenesis. A number of targeted anticancer drugs, such as small-molecule kinase inhibitors and monoclonal antibodies, have been evaluated in clinical trials with newly-diagnosed, as well as recurrent GBM. Unfortunately, to date, only a single anti-angiogenic agent, bevacizumab, has been approved for the treatment of recurrent GBM in the USA and Canada. The novel possibilities of cancer immunotherapy, especially immune checkpoint inhibitors, are being evaluated in clinical trials of patients with GBM. The most recent clinical experiences with targeted therapy as well as immunotherapy of GBM are given in this review. The relative lack of success of some of these approaches recently revealed in well-designed randomized clinical trials is also discussed.
Keywords: CTLA4 inhibition; GBM; Glioblastoma multiforme; PD1 inhibition; clinical trials; immune checkpoint inhibitors; immunotherapy; personalized medicine; review; targeted therapy.
Copyright© 2017 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Similar articles
-
New molecularly targeted therapies for glioblastoma multiforme.Anticancer Res. 2012 Jul;32(7):2935-46. Anticancer Res. 2012. PMID: 22753758 Review.
-
Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.Anticancer Res. 2015 Mar;35(3):1229-35. Anticancer Res. 2015. PMID: 25750269 Review.
-
[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].Bull Cancer. 2016 May;103(5):484-98. doi: 10.1016/j.bulcan.2016.02.014. Epub 2016 Mar 28. Bull Cancer. 2016. PMID: 27032303 Review. French.
-
Current Immunotherapies for Glioblastoma Multiforme.Front Immunol. 2021 Mar 9;11:603911. doi: 10.3389/fimmu.2020.603911. eCollection 2020. Front Immunol. 2021. PMID: 33767690 Free PMC article. Review.
-
The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.Expert Rev Anticancer Ther. 2014 Aug;14(8):955-64. doi: 10.1586/14737140.2014.916214. Epub 2014 May 12. Expert Rev Anticancer Ther. 2014. PMID: 24814143 Review.
Cited by
-
Understanding the role of endothelial cells in brain tumor formation and metastasis: a proposition to be explored for better therapy.J Natl Cancer Cent. 2023 Aug 6;3(3):222-235. doi: 10.1016/j.jncc.2023.08.001. eCollection 2023 Sep. J Natl Cancer Cent. 2023. PMID: 39035200 Free PMC article. Review.
-
Nerve Growth Factor, Antimicrobial Peptides and Chemotherapy: Glioblastoma Combination Therapy to Improve Their Efficacy.Biomedicines. 2023 Nov 9;11(11):3009. doi: 10.3390/biomedicines11113009. Biomedicines. 2023. PMID: 38002009 Free PMC article.
-
HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies.Onco Targets Ther. 2023 Oct 24;16:849-865. doi: 10.2147/OTT.S425523. eCollection 2023. Onco Targets Ther. 2023. PMID: 37899986 Free PMC article. Review.
-
Unraveling the signaling mechanism behind astrocytoma and possible therapeutics strategies: A comprehensive review.Cancer Rep (Hoboken). 2023 Oct;6(10):e1889. doi: 10.1002/cnr2.1889. Epub 2023 Sep 7. Cancer Rep (Hoboken). 2023. PMID: 37675821 Free PMC article. Review.
-
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines.Int J Mol Sci. 2023 Apr 27;24(9):7929. doi: 10.3390/ijms24097929. Int J Mol Sci. 2023. PMID: 37175636 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous